Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

KORU Medical Q3 revenue rises 11% year-over-year

By Reuters News


Overview

  • U.S. medical device maker's Q3 revenue rose 11% yr/yr to $11.6 mln

  • Company posted second straight quarter of positive net income and adjusted EBITDA

  • Company raised full-year 2026 revenue guidance to $48.0-$48.5 mln


Outlook

  • KORU Medical raises 2026 revenue guidance to $48.0-$48.5 mln from $47.5-$48.5 mln

  • Company now sees 2026 gross margin at 63-64%, up from prior 62-64% range

  • Company raises year-end 2026 cash balance forecast to over $8.0 mln


Result Drivers

  • DOMESTIC GROWTH - Higher pump and consumable volumes, new patient starts, and market share gains drove domestic revenue increase

  • MARGIN IMPROVEMENT - Gross margin rose due to lower manufacturing costs, favorable customer mix, and tariff rebates

  • INTERNATIONAL VARIATION - International revenue declined due to a strong prior-year comparison, partly offset by new patient starts


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income

$218,000

Q3 Gross Margin

65.2%

Q3 Operating Expenses

$7.36 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for KORU Medical Systems Inc is $6.00, about 85.8% above its November 9 closing price of $3.23

  • The stock recently traded at 304 times the next 12-month earnings vs. a P/E of 28,848 three months ago


Reuters Recommended Reads

  • Nov 9 - Myomo Q3 revenue rises 22% to record high

  • Nov 10 - LENSAR Q3 revenue slightly misses estimates on slower surgical scheduling

  • Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.